Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/pai.13995 | DOI Listing |
JAMA Ophthalmol
January 2025
John A. Moran Eye Center, Department of Ophthalmology & Visual Sciences, Department of Neurology, University of Utah Health, Salt Lake City.
Importance: Nearly 2% of the US population received a prescription for semaglutide in 2023. There has been a recent concern that this drug and other similar medications may be associated with ophthalmic complications.
Objective: To report ophthalmic complications associated with the use of semaglutide or tirzepatide.
Discov Nano
January 2025
School of Biosciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, 632014, India.
Osteosarcoma (OS) is distinguished as a high-grade malignant tumor, characterized by rapid systemic metastasis, particularly to the lungs, resulting in very low survival rates. Understanding the complexities of tumor development and mutation is the need of the hour for the advancement of targeted therapies in cancer care. A significant innovation in this area is the use of nanotechnology, specifically nanoparticles, to tackle various challenges in cancer treatment.
View Article and Find Full Text PDFMicrobiology (Reading)
January 2025
Instituto de Microbiologa, Colegio de Ciencias Biolgicas y Ambientales, Universidad San Francisco de Quito, Quito, Ecuador.
Antimicrobial resistance (AMR) is a major threat to global public health that continues to grow owing to selective pressure caused by the use and overuse of antimicrobial drugs. Resistance spread by plasmids is of special concern, as they can mediate a wide distribution of AMR genes, including those encoding extended-spectrum -lactamases (ESBLs). The CTX-M family of ESBLs has rapidly spread worldwide, playing a large role in the declining effectiveness of third-generation cephalosporins.
View Article and Find Full Text PDFJ Am Chem Soc
January 2025
Shanghai Key Laboratory of Green Chemistry and Chemical Processes, School of Chemistry and Molecular Engineering, East China Normal University, Dongchuan Road 500, Shanghai 200241, P. R. China.
Host-guest supramolecular fluorescence probes have garnered significant attention in the detection and sensing of bioactive molecules due to their functionalization potential, adjustable physical properties, and high specificity. However, such probes that reliably, rapidly, and specifically measure neurotransmitter dynamics at the cellular and in vivo level have yet to be reported. Herein, we present a supramolecular fluorescent chemosensor designed for norepinephrine (NE) detection, showing an exceptional response and specificity through host-guest complexation.
View Article and Find Full Text PDFHealth Secur
January 2025
Richard C. White, PhD, is an Interdisciplinary Scientist, Medical Countermeasures Program; Peter L. Adams, PhD, and Karl J. Erlandson, PhD, are Interdisciplinary Scientists, and Ramya Natarajan, PhD, is a Health Scientist, Influenza and Emerging Infectious Diseases Division; Kyla A. Britson, PhD, Rushyannah Killens-Cade, PhD, and Malen A. Link, PhD, are Interdisciplinary Scientists, and Daniel N. Wolfe, PhD, is Deputy Director, Division of Chemical, Biological, Radiological, and Nuclear (CBRN) Countermeasures; Derek L. Eisnor, MD, is a Medical Officer, Division of Clinical Development; Brenda L. Fredericksen, PhD, is Program Director, Nonclinical Research Program, and James Little, MS, is a Senior Scientific Advisor, Division of Nonclinical Development; John S. Lee, PhD, is Program Director, Molecular Diagnostics Program, and Julie M. Villanueva, PhD, is a Scientific Advisor, Detection, Diagnostics, and Devices Infrastructure Division; Kimberly L. Sciarretta, PhD, is Program Director, Launch Office, Division of Research, Innovation, and Ventures; and Robert A. Johnson, PhD, is Director, Medical Countermeasures Program; all at the Biomedical Advanced Research and Development Authority, Washington, DC. Gerald R. Kovacs, PhD, is a Senior Advisor; Huyen Cao, MD, is a Senior Clinical Studies Analyst; Christopher Dale, PhD, and Mark Michalik, MBA, are Senior Subject Matter Experts; Mario H. Skiadopoulos, PhD, is a Preclinical Drug Development Subject Matter Expert; and Xiaomi Tong, PhD, is a Senior Regulatory Affairs Subject Matter Expert; all at Tunnell Government Services, Berwyn, PA. Suchismita Chandran, PhD, is a Lead Associate, and Michael Rowe, MS, is a Senior Consultant; both at Booz Allen Hamilton, McLean, VA. Ethan J. Fritch, PhD, is an ORISE Fellow, Oak Ridge Institute for Science and Education, Oak Ridge, TN. George Robertson, PhD, is Chief Scientific Officer, Cambra Consulting, Inc., Woodbridge, VA.
The COVID-19 pandemic has revealed the need for nations to prepare more effectively for emerging infectious diseases. Preparing for these threats requires a multifaceted approach that includes assessing pathogen threat, building flexible capabilities for rapid medical countermeasure (MCM) development, and exercising, maintaining, and improving those response capabilities. The Biomedical Advanced Research and Development Authority (BARDA) promotes the advanced development of MCMs in response to natural and manmade threats.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!